Single agent chemotherapy (actinomycin D) in the treatment of metastatic testicular carcinoma.
Single-agent chemotherapy (actinomycin D) was administered in cyclic regimens to 26 patients with metastatic, nonseminomatous testicular carcinoma. Twenty-five patients were evaluable, 9 with stage II disease and 16 with stage III disease. A 37.5% response rate in stage III disease is reported and all patients are long-term survivors. Five of eight stage II patients currently being followed are alive and well. During toxicity was negligible. Actinomycin D is recommended as the initial drug of choice for metastatic testicular carcinoma.
D002822:Choriocarcinoma / Q000188:drug therapy* / Q000401:mortality; D003609:Dactinomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D004407:Dysgerminoma / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D009362:Neoplasm Metastasis; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy; D013724:Teratoma / Q000188:drug therapy* / Q000401:mortality; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000401:mortality
D003609:Dactinomycin